Corporate
Presentation
March 2024
www.nucana.com
Disclaimer
Forward-Looking Statements
This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained
in this presentation are forward-looking statements. Forward-looking statements include information concerning the company's planned and ongoing preclinical and clinical studies for the Company's product candidates and the potential advantages of those product candidates, including NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of the Company's planned and ongoing clinical studies; the impact of COVID-19 on its preclinical studies, clinical studies, business, financial condition and results of operations; the utility of prior preclinical and clinical data in determining future clinical results; the timing or likelihood of regulatory filings and approvals for any of its product candidates; the Company's intellectual property; the amount and sufficiency of the Company's cash and cash equivalents to achieve its projected milestones and to fund its planned operations into 2025; and estimates regarding the Company's expenses, future revenues and future capital requirements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of our Annual Report on Form 20-F for the year ended December 31, 2022 filed with the Securities and Exchange Commission ("SEC") on April 4, 2023, and subsequent reports that the Company files with the SEC.
Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this presentation. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except
as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this presentation to conform any of the forward-looking statements to actual results or to changes in its expectations.
Trademarks
NuCana, the NuCana logo and other trademarks or service marks of NuCana plc appearing in this presentation are the property of NuCana plc. Trade names, trademarks and service marks of other companies appearing in this presentation are the property of their respective owners. Solely for convenience, the trademarks, service marks and trade names referred to in this presentation may be without the ® and ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights to these trademarks, service marks and trade names.
Harnessing the Power of Phosphoramidate Chemistry
A New Era in Oncology
Nucleoside Analogs: Cornerstones of Cancer Treatment
16 FDA Approved Anti-Cancer Nucleoside Analogs
Peak Year Sales
Limitations of Nucleoside Analogs
Breakdown | Uptake | Activation | Administration |
& Toxic | Dependent on | Inefficient | Challenges |
Byproducts | transporters | generation of | Poor PK leads to |
Off-target | to enter | anti-cancer | sub-optimal |
toxicity | cancer cells | metabolites | dosing |
Transforming Nucleoside Analogs into ProTides
ProTides: A New Era In Anti-Virals
$701 | $942 | $14 | 3 |
billion | billion | billion |
Hepatitis C | HIV | COVID-19 |
Transforms Therapeutic Index
Overcomes Viral Resistance Mechanisms
- Sovaldi + Harvoni + Epclusa + Vosevi cumulative sales through December 31, 2023
- Genvoya + Descovy + Odefsey + Biktarvy + Symtuza cumulative sales through December 31, 2023
- Veklury cumulative sales through December 31, 2023
ProTides: A New Era in Oncology
300x | 185x |
More potent | More potent |
than | than |
5-FU1 | 3'-dA2 |
Transforms Therapeutic Index
Overcomes Cancer Resistance Mechanisms
- Pre-clinicaldata - Ghazaly et al (ESMO September 2017)
- Pre-clinicaldata - Symeonides et al (ESMO September 2020)
Current Development Status
INDICATION
Study | Colorectal Cancer |
Study | Colorectal Cancer |
randomized
Solid Tumors
Study
Lung Cancer
Solid Tumors
Study
Solid Tumors
COMBINATION | PRE-CLINICAL | PHASE 1 | PHASE 2 | PHASE 3 |
irinotecan
bevacizumab
oxaliplatin bevacizumab
irinotecan
bevacizumab
pembrolizumab
docetaxel
monotherapy
pembrolizumab
Strong Balance Sheet & Multiple Inflection Points
NCNA
Cash & Cash Equivalents | Cash Runway | Important Data Readouts |
September 30, 2023 | into | throughout |
~$22 million# | 2025 | 2024 |
#Based on exchange rate of £1.00 to $1.22 as of September 30, 2023
Study - Solid Tumors - Phase 1
Study - Colorectal Cancer - Phase 1b/2 (ongoing)
Study - Colorectal Randomized - Phase 2 (ongoing)
Study - Advanced Solid Tumors - Phase 1b/2 (ongoing)
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
NuCana plc published this content on 12 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 March 2024 11:07:02 UTC.